• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
NSB
Click for more information
3.77% 5.5¢

NEUROSCIENTIFIC BIOPHARMACEUTICALS LTD - Charts / Financials

Market Cap $7.953M  ! watchlist Created with Sketch. Add to my watchlist
Healthcare Biotechnology

NeuroScientific Biopharmaceuticals Limited is an Australia-based company that is engaged... NeuroScientific Biopharmaceuticals Limited is an Australia-based company that is engaged in developing peptide-based pharmaceutical drugs that target a number of neurodegenerative conditions with high unmet medical demand. The Company’s product portfolio includes EmtinB, a therapeutic peptide initially targeting Alzheimer’s disease and glaucoma, as well as other Emtin peptides (EmtinAc, EmtinAn, and EmtinBn), which have demonstrated similar therapeutic potential as EmtinB. EmtinB is a peptide-based compound that binds to surface-based cell receptors from the LDLR family, activating intracellular signalling pathways that stimulate neuroprotection, neuroregeneration and modulate neuroinflammation. EmtinB is modelled on a specific active domain of the complex human protein called Metallothionein-IIA, which is produced as part of the human body’s innate immune response to cell injury. More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits
refresh Created with Sketch. REFRESH
Last update - 13.17pm 03/05/2024 (20 minute delay) ?
Day
Open 5.3¢   Day High 5.5¢   Day Low 5.3¢
Daily Volume 19470
Bids   Sellers
Number Price Volume   Number Price Volume
1 5.2¢ 15688   2 5.5¢ 211999

Directors & Senior Management

Mr. Dougal Thring Chief Operating Officer
Mr. Anthony Keating Executive Director
Dr. Anton Uvarov Executive Director
Mr. Simon Scott Director of Clinical Development
Mr. Chris Achurch Company Secretary
Mr. Christopher Ntoumenopoulos Non-Executive Chairman of the Board
Mr. Clarke Barlow Non-Executive Director

Data source: Refinitiv

(20min delay)
Last
5.5¢ 		Change
0.002(3.77%) 		Mkt cap ! $7.953M
Open High Low Value Volume
5.3¢ 5.5¢ 5.3¢ $1.035K 19.47K

Buyers (Bids)

No. Vol. Price($)
1 15688 5.2¢
 

Sellers (Offers)

Price($) Vol. No.
5.5¢ 211999 2
View Market Depth
Last trade - 16.10pm 03/05/2024 (20 minute delay) ?
Last
5.3¢ 		  Change
0.002 ( 3.92 %)
Open High Low Volume
5.4¢ 5.4¢ 5.3¢ 2796
Last updated 13.17pm 03/05/2024 ?

Top Stories

Patagonia shares rise above 20% on lithium grades at maiden well in Argentina

Patagonia Lithium shares rise above 12 percent on lithium grading nearly 600 parts per million at the first drill well of its Argentinian Formentera Lithium Project.
Macquarie profits fall 32% on 'market volatility' and low-achieving 'green investments' Macquarie Group Ltd (ASX:MQG) has shaved more than 30 percent off its net profit in the final quarter of the 2024 financial year (FY 2024), compared to the same time last year, with executives speaking cautiously about market volatility and @lower asset realisations’ from green in...
Car EV-olution accelerates Oz into pole position As the world steers towards a more sustainable future, the surge in electric vehicle (EV) sales is turning industries upside down, and mining is no exception. Australia, famous for its treasure trove of minerals, finds itself right in the middle of this shift, which raises two questions. Firstly,...
Provident Aurum's off-market bid sends Sihayo shares soaring Small-cap mineral and gold explorer, Sihayo Gold (ASX:SIH) shares have soared, on news that the company has received intentions from Provident Aurum Pte to make an off-market takeover offer to acquire all shares of Sihayo Gold.
Why Princeton Professor rates BlinkLab's autism & ADHD screening app In this interview with Sonia Madigan, Professor Sam Wang of Princeton University discusses the development and potential of BlinkLab's (ASX:BB1) AI-driven smartphone app, designed to screen for autism and ADHD.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.